#biopharma

Boehringer Ingelheim has named Christie Bloomquist to a senior US human pharma and foundation role, while BlueRock Therapeutics is seeing the departure of its chief scientific officer.

Amgen has filed a supplement to update the Tavneos label with additional warning information as the FDA continues pushing to withdraw the drug.

Anthropic’s appointment of Novartis CEO Vas Narasimhan to its board points to a closer alignment between frontier AI development and the pharmaceutical industry.

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

New research says early-stage drug development has nearly doubled worldwide over the past decade and moved from a U.S.-dominated model to a dual hub centered on the United States and China.

Biopharma companies are restructuring international licensing agreements to reduce their exposure to Most Favored Nation pricing rules, which link US drug prices to the lowest prices paid in other countries.